Next Article in Journal
Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study
Next Article in Special Issue
Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
Previous Article in Journal
Viral Infection at High Magnification: 3D Electron Microscopy Methods to Analyze the Architecture of Infected Cells
Previous Article in Special Issue
Natural Products as Tools for Defining How Cellular Metabolism Influences Cellular Immune and Inflammatory Function during Chronic Infection
Open AccessReview

Virologic Tools for HCV Drug Resistance Testing

National Reference Center for Viral Hepatitis B, C, and D; Department of Virology, Hôpital Henri Mondor, Université Paris-Est and INSERM U955, Créteil 94010, France
*
Author to whom correspondence should be addressed.
Academic Editor: Thomas F. Baumert
Viruses 2015, 7(12), 6346-6359; https://doi.org/10.3390/v7122941
Received: 18 September 2015 / Revised: 28 November 2015 / Accepted: 30 November 2015 / Published: 4 December 2015
(This article belongs to the Special Issue HCV Drug Resistance)
Recent advances in molecular biology have led to the development of new antiviral drugs that target specific steps of the Hepatitis C Virus (HCV) lifecycle. These drugs, collectively termed direct-acting antivirals (DAAs), include non-structural (NS) HCV protein inhibitors, NS3/4A protease inhibitors, NS5B RNA-dependent RNA polymerase inhibitors (nucleotide analogues and non-nucleoside inhibitors), and NS5A inhibitors. Due to the high genetic variability of HCV, the outcome of DAA-based therapies may be altered by the selection of amino-acid substitutions located within the targeted proteins, which affect viral susceptibility to the administered compounds. At the drug developmental stage, preclinical and clinical characterization of HCV resistance to new drugs in development is mandatory. In the clinical setting, accurate diagnostic tools have become available to monitor drug resistance in patients who receive treatment with DAAs. In this review, we describe tools available to investigate drug resistance in preclinical studies, clinical trials and clinical practice. View Full-Text
Keywords: HCV; RAVs; resistance; tools; direct-acting antivirals HCV; RAVs; resistance; tools; direct-acting antivirals
MDPI and ACS Style

Fourati, S.; Pawlotsky, J.-M. Virologic Tools for HCV Drug Resistance Testing. Viruses 2015, 7, 6346-6359.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop